# Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

> **NCT02049294** · PHASE2,PHASE3 · COMPLETED · sponsor: **McMaster University** · enrollment: 11 (actual)

## Conditions studied

- Steroid and/or Prednisone Dependent Asthma
- Eosinophilic Bronchitis

## Interventions

- **BIOLOGICAL:** Omalizumab (Xolair)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02049294
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049294, "Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02049294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*